Around 5,700 people with early breast cancer are set to benefit from expanded access to a treatment combination designed to help prevent their cancer from returning, following our recommendation, ...

The technologies could help healthcare professionals spot hidden spinal fractures in patients undergoing routine CT scans have been conditionally recommended in draft guidance.

We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing ...

Licensed for use in the UK in March, Alyftrek will now be immediately funded by the NHS in England. This rapid timeline demonstrates NICE's commitment to getting breakthrough treatments to patients ...

Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults. Last reviewed: ...

Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults. Last ...

This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years.

Early value assessment (EVA) guidance on artificial intelligence technologies to help detect fractures on X-rays in urgent care. Last reviewed: 14 January 2025 Next review: This guidance will be ...

Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2‑negative gastric or gastro-oesophageal junction ...

Benefits of new Alzheimer’s treatment lecanemab are too small to justify the cost to the NHS Our draft recommendation follows analysis of clinical trial evidence and reviewing the benefits of slowing ...

NICE is unable to make a recommendation about the use in the NHS of baricitinib (Olumiant) for treating juvenile idiopathic arthritis in people 2 years and over. This is because Eli Lilly did not ...

Hybrid closed loop (HCL) systems are recommended as an option for managing blood glucose levels in type 1 diabetes for adults who have an HbA1c of 58 mmol/mol (7.5%) or more, or have disabling ...